Analyst Site Visit

Cambridge Antibody Tech Group PLC
17 September 2003


03/CAT/24

FOR IMMEDIATE RELEASE

07.00 BST, 02.00 EST Wednesday 17 September 2003


For further information contact:

Cambridge Antibody Technology                      Weber Shandwick Square Mile (Europe)
Tel: [phone]                          Tel: [phone]
Peter Chambre, Chief Executive Officer             Kevin Smith
John Aston, Chief Financial Officer                Rachel Lankester
Rowena Gardner, Director of Corporate
Communications
                                                   BMC Communications/The Trout Group (USA)
                                                   Tel: [phone]
                                                   Brad Miles, ext 17 (media)
                                                   Brandon Lewis, ext 15 (investors)




CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCES
ANALYSTS SITE VISIT

Cambridge, UK... Cambridge Antibody Technology (LSE:CAT; NASDAQ: CATG)
announces that it is holding an Analysts site visit at its Granta Park location
today. The focus of the day will be CAT's product candidate pipeline and
technology. Subjects for discussion include Ribosome Display, anti-IL13 antibody
therapeutics and patent licensing. The presentations will be webcast
simultaneously from 10.00 BST and can be viewed through CAT's website
www.cambridgeantibody.com. An archive will be available through the website for
thirty days thereafter.


-ENDS-



Cambridge Antibody Technology (CAT):

•  CAT is a UK-based biotechnology company using its proprietary
technologies and capabilities in human monoclonal antibodies for drug discovery
and drug development. Based near Cambridge, England, CAT currently employs
around 290 people.

•  CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for rapidly
isolating human monoclonal antibodies using phage display and ribosome display
systems. CAT has extensive phage antibody libraries, currently incorporating
more than 100 billion distinct antibodies. These libraries form the basis for
the Company's strategy to develop a portfolio of antibody-based drugs.

•  HUMIRATM, the leading CAT-derived antibody, isolated and optimised in
collaboration with Abbott has been approved by the US Food and Drug
Administration for marketing in the US and by the European Commission for
marketing in the EU as a treatment for rheumatoid arthritis.

•  Eight further CAT-derived human therapeutic antibodies are at various
stages of clinical trials. There are five candidate therapeutic antibodies in
pre-clinical development.

•  CAT has alliances with a number of pharmaceutical and biotechnology
companies to discover, develop and commercialise human monoclonal antibody-based
products. CAT has co-development programmes with Amgen, Amrad, Elan and Genzyme.

•  CAT has also licensed its proprietary technologies to several companies.
CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences,
Merck & Co, Pfizer and Wyeth Research.

•  CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering in
March 2000.


Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding CAT's present and future business strategies and
the environment in which CAT will operate in the future. Certain factors that
could cause CAT's actual results, performance or achievements to differ
materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative
arrangements, success of product candidates in clinical trials, regulatory
developments and competition.


                      This information is provided by RNS
            The company news service from the London Stock Exchange        CBIGDCSGBGGXL